ALX Oncology Holdings

ALXO · NASDAQ

$1.24+$0.10 (+8.77%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $1.14

Latest news

NewsOct 16, 1:05 PM ET
12 Health Care Stocks Moving In Friday's Intraday Session
Press releaseSep 28, 8:00 AM ETGlobe Newswire
ALX Oncology Announces Nature Medicine Publication of ASPEN-06 Phase 2 Clinical Data Demonstrating Strong Responses and Durable Clinical Benefit with Evorpacept in HER2-Positive Gastric Cancer
Press releaseAug 6, 8:00 AM ETGlobe Newswire
ALX Oncology Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Press releaseJun 30, 8:00 AM ETGlobe Newswire
ALX Oncology Appoints Scott Garland as Chairman of the Board and Michael Listgarten as General Counsel
Press releaseMay 8, 8:00 AM ETGlobe Newswire
ALX Oncology Reports First Quarter 2026 Financial Results and Provides Corporate Update
Press releaseMay 7, 8:00 AM ETGlobe Newswire
ALX Oncology's Evorpacept in Combination with Zanidatamab Generates Promising, Durable Response in Patients with Advanced HER2-Positive Breast Cancer and High CD47 Expression
Press releaseApr 13, 8:30 AM ETGlobe Newswire
ALX Oncology Appoints Jeff Knight as Chief Development and Operating Officer
Press releaseFeb 27, 8:00 AM ETGlobe Newswire
ALX Oncology Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
NewsFeb 27, 6:11 AM ET
Earnings Scheduled For February 27, 2026
NewsFeb 26, 10:02 AM ET
A Look Ahead: ALX Oncology Holdings's Earnings Forecast
NewsFeb 5, 7:05 AM ET
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Press releaseJan 30, 8:15 AM ETGlobe Newswire
New Data Demonstrate CD47 Expression Level Helps Predict Response to ALX Oncology's Evorpacept in Combination with Ziihera (zanidatamab-hrii) in Advanced HER2-Positive Breast Cancer
Press releaseJan 8, 8:30 AM ETGlobe Newswire
ALX Oncology Advances Separate Clinical Trials Evaluating Investigational CD47-Inhibitor Evorpacept and Novel EGFR-Targeted Antibody-Drug Conjugate ALX2004
Press releaseDec 7, 8:00 AM ETGlobe Newswire
ALX Oncology Announces Positive Results from Ongoing Investigator-Sponsored Phase 2 Trial Evaluating Evorpacept in Combination with Standard-of-Care Treatment in Patients with Indolent B-cell Non-Hodgkin Lymphoma, at ASH Annual Meeting
Press releaseNov 19, 9:45 AM ETGlobe Newswire
Targeted Cancer Therapies Gain Momentum as Precision Market Surges Past $106B
Press releaseNov 7, 8:15 AM ETGlobe Newswire
ALX Oncology Reports Third Quarter 2025 Financial Results and Provides Corporate Update
NewsNov 7, 6:11 AM ET
Earnings Scheduled For November 7, 2025
NewsNov 6, 1:02 PM ET
Examining the Future: ALX Oncology Holdings's Earnings Outlook
NewsAug 19, 8:08 AM ET
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
NewsAug 19, 8:01 AM ETAvi Kapoor
Why Palo Alto Shares Are Trading Higher By Around 7%; Here Are 20 Stocks Moving Premarket
NewsAug 18, 5:06 PM ET
12 Health Care Stocks Moving In Monday's After-Market Session
NewsAug 13, 5:06 PM ET
12 Health Care Stocks Moving In Wednesday's After-Market Session
Press releaseAug 12, 4:05 PM ETGlobe Newswire
ALX Oncology Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Press releaseMay 8, 8:30 AM ETGlobe Newswire
ALX Oncology Reports First Quarter 2025 Financial Results and Provides Corporate Update
NewsMay 8, 4:33 AM ET
Earnings Scheduled For May 8, 2025
NewsMay 7, 12:10 PM ET
What's Next: ALX Oncology Holdings's Earnings Preview
Press releaseMar 8, 7:33 AM ETPRNewswire
Why the Global Cancer Market Could Surpass $900 Billion--And the Stocks Leading the Charge
Press releaseMar 6, 4:01 PM ETGlobe Newswire
ALX Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
Press releaseJan 22, 9:00 AM ETPRNewswire
Oncology's Best Minds Set to Meet at Upcoming 2025 ASCO Gastrointestinal Cancers Symposium
Press releaseJan 7, 8:00 AM ETGlobe Newswire
ALX Oncology to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Press releaseDec 12, 8:00 AM ETGlobe Newswire
ALX Oncology to Host Virtual Company Event Highlighting New Clinical Data Presented at SABCS 2024
Press releaseNov 26, 8:00 AM ETGlobe Newswire
ALX Oncology to Participate in the Piper Sandler 36th Annual Healthcare Conference
Press releaseNov 7, 4:00 PM ETGlobe Newswire
ALX Oncology Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Press releaseNov 4, 8:00 AM ETGlobe Newswire
ALX Oncology Announces November Investor Conference Participation
Press releaseSep 9, 8:00 AM ETGlobe Newswire
ALX Oncology to Present at the 2024 Cantor Fitzgerald Global Healthcare Conference
NewsAug 27, 8:54 AM ETAvi Kapoor
Top 3 Health Care Stocks Which Could Rescue Your Portfolio This Month
Press releaseAug 8, 4:05 PM ETGlobe Newswire
ALX Oncology Reports Second Quarter 2024 Financial Results and Provides Corporate Update
NewsAug 1, 2:34 PM ETAvi Kapoor
Crude Oil Moves Lower; Moderna Shares Plunge
NewsAug 1, 12:06 PM ETAvi Kapoor
Dow Dips Over 500 Points; ISM Manufacturing PMI Falls In July
NewsAug 1, 10:15 AM ETAvi Kapoor
Nasdaq Surges 1%; Meta Posts Upbeat Earnings
NewsAug 1, 8:32 AM ETAvi Kapoor
Why Carvana Shares Are Trading Higher By 13%; Here Are 20 Stocks Moving Premarket
NewsAug 1, 8:21 AM ET
Market-Moving News for August 1st

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.

Latest news

12 Health Care Stocks Moving In Friday's Intraday Session

ALX Oncology Announces Nature Medicine Publication of ASPEN-06 Phase 2 Clinical Data Demonstrating Strong Responses and Durable Clinical Benefit with Evorpacept in HER2-Positive Gastric Cancer

ALX Oncology Reports Second Quarter 2026 Financial Results and Provides Corporate Update

ALX Oncology Appoints Scott Garland as Chairman of the Board and Michael Listgarten as General Counsel

ALX Oncology Reports First Quarter 2026 Financial Results and Provides Corporate Update

ALX Oncology's Evorpacept in Combination with Zanidatamab Generates Promising, Durable Response in Patients with Advanced HER2-Positive Breast Cancer and High CD47 Expression

ALX Oncology Appoints Jeff Knight as Chief Development and Operating Officer

ALX Oncology Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

Earnings Scheduled For February 27, 2026

A Look Ahead: ALX Oncology Holdings's Earnings Forecast

12 Health Care Stocks Moving In Thursday's Pre-Market Session

New Data Demonstrate CD47 Expression Level Helps Predict Response to ALX Oncology's Evorpacept in Combination with Ziihera (zanidatamab-hrii) in Advanced HER2-Positive Breast Cancer

ALX Oncology Advances Separate Clinical Trials Evaluating Investigational CD47-Inhibitor Evorpacept and Novel EGFR-Targeted Antibody-Drug Conjugate ALX2004

ALX Oncology Announces Positive Results from Ongoing Investigator-Sponsored Phase 2 Trial Evaluating Evorpacept in Combination with Standard-of-Care Treatment in Patients with Indolent B-cell Non-Hodgkin Lymphoma, at ASH Annual Meeting

Targeted Cancer Therapies Gain Momentum as Precision Market Surges Past $106B

ALX Oncology Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Earnings Scheduled For November 7, 2025

Examining the Future: ALX Oncology Holdings's Earnings Outlook

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

Why Palo Alto Shares Are Trading Higher By Around 7%; Here Are 20 Stocks Moving Premarket

12 Health Care Stocks Moving In Monday's After-Market Session

12 Health Care Stocks Moving In Wednesday's After-Market Session

ALX Oncology Reports Second Quarter 2025 Financial Results and Provides Corporate Update

ALX Oncology Reports First Quarter 2025 Financial Results and Provides Corporate Update

Earnings Scheduled For May 8, 2025

What's Next: ALX Oncology Holdings's Earnings Preview

Why the Global Cancer Market Could Surpass $900 Billion--And the Stocks Leading the Charge

ALX Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Oncology's Best Minds Set to Meet at Upcoming 2025 ASCO Gastrointestinal Cancers Symposium

ALX Oncology to Present at the 43rd Annual J.P. Morgan Healthcare Conference

ALX Oncology to Host Virtual Company Event Highlighting New Clinical Data Presented at SABCS 2024

ALX Oncology to Participate in the Piper Sandler 36th Annual Healthcare Conference

ALX Oncology Reports Third Quarter 2024 Financial Results and Provides Corporate Update

ALX Oncology Announces November Investor Conference Participation

ALX Oncology to Present at the 2024 Cantor Fitzgerald Global Healthcare Conference

Top 3 Health Care Stocks Which Could Rescue Your Portfolio This Month

ALX Oncology Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Crude Oil Moves Lower; Moderna Shares Plunge

Dow Dips Over 500 Points; ISM Manufacturing PMI Falls In July

Nasdaq Surges 1%; Meta Posts Upbeat Earnings

Why Carvana Shares Are Trading Higher By 13%; Here Are 20 Stocks Moving Premarket

Market-Moving News for August 1st